We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Theracryf Plc | LSE:TCF | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -2.50% | 0.975 | 2,485,502 | 09:49:20 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.90 | 1.05 | 1.00 | 0.975 | 1.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:34:39 | O | 1,961 | 0.90 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/6/2024 | 15:14 | UK RNS | Theracryf PLC Holding(s) in Company |
| 13/6/2024 | 07:00 | UK RNS | Theracryf PLC TheraCryf Research and Development Day |
| 04/6/2024 | 15:04 | UK RNS | Theracryf PLC Holding(s) in Company |
| 28/5/2024 | 19:12 | ALNC |  EARNINGS AND TRADING: Victorian Plumbing profit up; Xeros loss narrows |
| 28/5/2024 | 16:05 | UK RNS | Theracryf PLC Final Results - Correction |
| 28/5/2024 | 07:00 | UK RNS | Theracryf PLC Final Results |
| 22/5/2024 | 07:00 | UK RNS | Theracryf PLC Notice of R&D presentation |
| 20/5/2024 | 07:00 | UK RNS | Theracryf PLC Notice of Results |
| 02/5/2024 | 10:47 | UK RNS | Theracryf PLC Holding(s) in Company |
| 02/5/2024 | 07:00 | UK RNS | Theracryf PLC Chronos Integration Update |
Theracryf (TCF) Share Charts1 Year Theracryf Chart |
|
1 Month Theracryf Chart |
Intraday Theracryf Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 14/6/2024 | 11:17 | Theracryf the new Evgen onwards and upwards | 103 |
| 29/9/2017 | 15:06 | Terra Catalyst Fund | 114 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 16/6/2024 09:20 by Theracryf Daily Update Theracryf Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TCF. The last closing price for Theracryf was 1p.Theracryf currently has 274,888,117 shares in issue. The market capitalisation of Theracryf is £2,199,105. Theracryf has a price to earnings ratio (PE ratio) of -0.54. This morning TCF shares opened at 1p |
Posted at 12/6/2024 14:46 by clocktower Great volume once again, it seems to be building up a head of steam before tomorrows R & D update, which based on the buying of late is likely to send the share price a lot higher, as it is nodoubt very positive, as it is unlikely we would have seen the slow increase in the share price lately, if it were not. |
Posted at 06/6/2024 12:46 by clocktower Maybe a rumour of a fresh deal is doing the rounds or an agreememt with Stalica is leaking markth126.There is also likely to be a string of other news coming this quarter from other studies, these alone might have a huige impact, sending the share price back towards its highs in 2022, which might come as a welcome surprise. Under those circumstances, as you say the stock could be very hard to come by even if it became a multi bagger. |
Posted at 04/6/2024 20:03 by terrydevlin1 Good luck Mark and CT. Whilst the Stalicla deal is still live I can’t see how this can go down much lower. But that deal looks to be on the rocks IMO. The fact TCF no longer mentioned up to $5.5m expected this year in the full results and Stalicla also removed from their website that this would go into phase 2 in 2024, it doesn’t look good. If the deal collapses this share price will be 0.1p and it’s game over. I question where is the money going to come from to bankroll this company? TCF needs between £3m and £4m a year which is enormous sums of money.I’ve been doing alright recently on the virtual dogs at the bookies, I’d rather stick a grand on a virtual dog than this dog of a share. |
Posted at 28/5/2024 17:15 by xxproinvestorxx Tcf FY26E is March 31st 2026. |
Posted at 28/5/2024 17:14 by xxproinvestorxx I didn't hear that in the presentation, however, when writing going concerns they can only report on what happened in the reported period, not after, except for the part that mentions post period. Also look at the research notes issued today, they also say cash into 2026. Say they expect TCF to "close FY26E with a closing cash balance of just under 0.3m" |
Posted at 28/5/2024 07:52 by terrydevlin1 Clock, there is no way this can go blue today, there is nothing positive in the update. I predict a 35% drop in share price today. You would have to be crazy to invest in this now, a share placing is inevitable in early autumn which would effectively end this share as an investment. |
Posted at 26/5/2024 12:34 by terrydevlin1 I don’t know how anyone can think the results will be positive at all. Terrible 12 months here. No income, Juvenesense deal collapsed, Stalicla dispute, no new contracts signed, a share placing, money running out, next to no news on SFX-01 progressing. I think TCF may have a decent drug in SFX-01 buy they can’t afford to do any trials and can’t get anyone to trial it for them. Even if TCF get the $5.5m they hoped by the end of the year, where is the next income coming from? Stalicla payments clearly can’t be relied on. The end goal is already written here, another share placement which happens every 2 years is inevitable at some point. The shares will be diluted so much that there is no possibility of shareholders making any money here. There is no hope of TCF ever succeeding now. Don’t waste your time or money here. |
Posted at 24/5/2024 10:23 by clocktower Seems to be falling in advance of the accounts, which everyone has been aware of for some time will be showing a substaintial loss but it seems to me the MM are lining up to drop it further, to see if they can get panicked sellers, and then there might be an opening to buy into an upward bounce.So I might jump in again after the results. It was pretty clear this was going to occur when there were buys of over 1.5 million at mid price earlier this week, and no tick up. Good Luck for next week and good trading. |
Posted at 10/5/2024 07:12 by terrydevlin1 I agree with your comment Clock Tower. It is incredibly disappointing to have no new deals signed up for SFX-01 since the Stalicla deal. There seems so little news now about SFX-01 in the past 10 months.The sad reality is that TCF cannot afford to do their own trials so they cannot do much to prove the drug is effective and it seems like they cannot get anyone to trial it for them. The Stalicla deal is so huge to TCF that they have no option but to wait for Stalicla to decide what they will do and when they will do it. It is TCF’s only potential income stream and money is running out. It is over a quarter of a year since the dispute was issued and no news at all. It doesn’t feel like there will be any news any time soon either. I feel for all investors who invested as a result of the Stalicla deal announcement in 2022. At that time with £10m in the bank, Juvenesense having a deal with SFX-01 and milestone payments of up to $160m with Stalicla it seemed like this share had great potential. I wish I never had stumbled on that RNS. |
Posted at 02/5/2024 07:19 by clocktower Well markth126 all guff in that RNS as nothing about the due money from Stalicla.Have you rung shyster Jones and asked him what’s going on? From the looks of the share price it would seem that some of those 62 million new shares have been sold, bringing the stock price down. Good luck maybe there will be better news when the next RNS is released. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
